Last updated: September 25, 2021
Sponsor: University of Maryland, Baltimore
Overall Status: Terminated
Phase
4
Condition
Chest Pain
Congestive Heart Failure
Heart Failure
Treatment
N/AClinical Study ID
NCT03746002
HP-00082982
Ages 18-89 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Admission within 48 hours for acute decompensated heart failure with at least onesymptom and one sign of volume overload
- Receipt of loop diuretic prior to admission
- Plan to administer furosemide 120 - 160 mg IV bolus twice daily over the next 24 hourswith additional diuresis deemed necessary
- If patient is concurrently administered intravenous vasodilator or inotrope, the doseof vasodilator or inotrope must be stable for 6 hours prior to enrollment with a planto continue the same dose for the 24 hour duration of this study
Exclusion
Exclusion Criteria:
- Metolazone prescribed prior to admission
- Receipt of continuous intravenous infusion of furosemide
- Cirrhosis or end stage renal disease
- Non-English speaking patients
Study Design
Total Participants: 3
Study Start date:
January 01, 2019
Estimated Completion Date:
January 10, 2020
Study Description
Connect with a study center
University of Maryland Medical Center
Baltimore, Maryland 21201
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.